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Summary
When human peripheral blood lymphocytes (PBLs) from Epstein-Barr virus (EBV)-seropositive
donors are injected intraperitoneally into SCID mice, EBV+ B cell tumors develop within weeks.
A preliminary report (Mosier, D. E., R. J. Gulizia, S. M. Baird, D. D. Richman, D. B. Wilson,
R. I. Fox, and T J. Kipps. 1989. Blood. 74(Suppl. 1):52a) has suggested that such tumors resemble
the EBVpositive malignancy, Burkitt's lymphoma. The present work shows that generally the
human (hu) PBIrSCID tumors are distinct from Burkitt's lymphoma and instead resemble
lymphoblastoid cell lines (LCLs) generated by EBVinfection of normal B cells in vitro in terms
of. (a) their cell surface phenotype, with expression of B cell activation antigens and adhesion
molecules, (b) normal karyotype, and (c) viral phenotype,with expression of all the transformation-
associated EBV latent proteins and, in a minority of cells, productive cycle antigens. Indeed,
in vitro-transformed LCLs also grow when inoculated into SCID mice, the frequency of tumor
outgrowth correlating with the in vitro growth phenotype ofthe LCL which is itself determined
by the identity of the transforming virus (i.e., type 1 or type 2 EBV). Histologically the PB1.r
derived hu-SCID tumors resemble the EBV+ large cell lymphomas that develop in immuno-
suppressed patients and, like the human tumors, often present at multiple sites as individual
monoclonal or oligoclonal foci. The remarkableefficiencyoftumor development in the hu-SCID
model suggests that lymphomagenesis involves direct outgrowth of EBVtransformed B cells
without requirement for secondary genetic changes, and that selection on the basis of cell growth
rate alone is sufficient to explain the monoclonal/oligoclonal nature of tumor foci. EBV + large
cell lymphoma of the immunosuppressed may arise in a similar way.
T
he C.B-17 scid/scid mutant strain ofmouse (hereafter re-
ferred to as the SCID mouse) exhibits a severe combined
immunodeficiency characterized by the absence of mature B
and T lymphocytes (1); indeed, the mutation is thought to
affect a component of the recombinase enzyme system in-
volved in Ig and TCR gene rearrangements (2-4). The un-
expected finding that mice carrying the SCID mutation could
be grafted successfully with human (hu) haematopoietic cells
has opened the way to the use ofthe hu-SCID chimeric mouse
as a model for studying humanimmune-function in vivo (5-7).
In addition, one of the original papers describing such en-
graftment showed that SCID mice reconstituted with high
numbers of(hu-PBIJSCID mice)often developed lymphomas
of B cell origin ifthe donor lymphocytes were from individ-
uals with serological evidence of infection with EBV; these
tumors were shownto carry EBV DNA but were otherwise
poorly characterized (5). It was immediately apparent from
these studies that SCID mice could provide a potentially in-
teresting in vivo model of human B lymphomagenesis in-
volving an important viral pathogen.
EBV is a human herpesvirus that in vitro has potent growth
transforming activity for resting B lymphocytes but that in
vivo is carried as an asymptomatic and persistent infection
by >90% of adults worldwide. The virus is, however, con-
sistently associated with two types of B cell malignancies:
(a) large cell lymphomas which arisein immunocompromised
individuals such as post-transplant patients (8, 9), and (b)
the high incidence, or "endemic," form of Burkitt's lymphoma
(BL)t which is geographically restricted to equatorial regions
of Africa and Papua New Guinea where malaria is holoen-
1 Abbreviations used in thispaper. BL, Burkitt's lymphoma; LCL, lympho-
blastoid cell lines; NGS, normal goat serum; NRS, normal rabbit serum;
VCA, viral capsid antigen complex.
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type similar to that oflymphoblastoid cell lines (LCLs) gener-
ated by infection of normal resting B cells in vitro with EBV
(11, 12); this is characterized by high cell-surface expression
of various B cell-associated"activation" antigens such as CD23
and CD39, and ofthe adhesion molecules LFA1(CD11a/18),
LFA3 (CD58), and ICAM-1 (CD54). In contrast, BL cells
express none of these LCIrassociated antigens, with the pos-
sible exception of LFA1; instead they display other surface
markers (e.g., CD10 and CD77) consistent with their prob-
able germinal center origin (13). Furthermore, large cell
lymphomas appear to express the same spectrum of EBV
latent gene products as are constitutively expressed in all in
vitro-transformed LCLs, i.e., six nuclear antigens (EBNA
1, 2, 3a, 3b, 3c, and -LP) and two membrane-associated pro-
teins (LMP-1 and LMP-2), while BL cells express detectable
levels of EBNA 1 only, with downregulation of the other
EBV latent genes (14, 15).
These differences between the two forms of EBV+ lym-
phomain man reflect theirdifferent pathogenesis. Thus, large
cell lymphoma appears to be primarily a virus-driven lym-
phoproliferation, in which the outgrowth of EBVinfected
transformed B cells is possible because the host control mech-
anisms that normally prevent such outgrowth, in particular
the EBVspecific cytotoxic T cell response (16), are impaired.
The fact that such tumors can sometimes present as mono-
clonal foci (9, 17, 18) raises the possibility of a second genetic
event, in addition to EBVinduced growth transformation,
occurring before the emergence of a malignant clone. There
is as yet no firm evidence for such an event, and the tumors
do not show any consistent chromosome abnormalities. On
the other hand, endemic BL clearly has a multistep patho-
genesis involving: (a) EBV infection of a particular target cell
pool, (b) chronic malarial infection of the host, which causes
temporary immunosuppression (19) and chronic stimulation
of germinal center activity (20-22), and (c) a chromosome
translocation involving chromosome 8 and either chromo-
some 14, 2, or 22, which results in deregulated expression
of the c-myc protooncogene (23, 24), thereby giving the
affected cell an additional proliferative advantage.
Given these differences between EBVassociated large-cell
lymphomas and BL, it was of interest to characterize more
fully the EBV+ tumors that arise spontaneously in SCID-
hu chimeric mice, particularly in the light of a preliminary
report suggesting that such tumors are essentially BIrlike (25).
That report, and the fact that AIDS patients can in some
instances develop classic EBV+ BL (26), raised the possibility
that EBVinfected BL progenitor cells are more frequent in
asymptomatic virus carriers than had been previously thought.
Materials and Methods
Isolation of Human Lymphocytes and Generation of Cell Lines In
Vitro. PBLs were isolated from heparinized peripheral blood by
isopycnic centrifugation on Ficoll-Hypaque. Spontaneous LCLs car-
rying the donors own resident EBV strain were established by cul-
turing PBLs from EBV-seropositive individuals in the presence of
Cyclosporin A to avert any T cell-mediated regression ofoutgrowth
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(27). Other LCLs were generated by deliberate in vitro infection
ofPBL cells from EBVseronegative individuals with different iso-
lates of EBV (28) .
Generation ofHuman B Cell Tumors in SCID Mice.
￿
In the main
set of experiments, between 35 and 50 x 106 PBLs, isolated from
healthy donors ofknown EBV serological status, were washed with
PBS and injected intraperitoneally into SCID mice. In other ex-
periments, 5 x 106 cells from established LCLs were injected in-
traperitoneally. If animals became sick they were killed and autop-
sied. Tumors and other tissues of interest were dissected into two
or more pieces whichwere either: (a) fixedin 10% formaldehyde/sa-
line for immunohistologic analysis, (b) used for preparing viable
cell suspensions for cell surface phenotype analysis or for karyotyping,
or (c) snap-frozen in liquid nitrogen for later preparation ofcryostat
sections for immunofluorescence studies and for preparing DNA
and/or protein samples for Southern andWesternblots, respectively.
Histopathology and Immunohistochemistry.
￿
Tumors fixedin 10%
formal saline were processed to 2-pm paraffin wax-embedded sec-
tions for staining with hematoxylin-eosin, or 3-,um sections for
immunohistochemical staining. A routine avidin-biotin complex
(ABC) immunostaining schedule was used with the primary mu-
rine mAbs UCHL1 (CD45RO antibody; DAKO Ltd., High
Wycombe, UK) for the detection of T cells, and L26 (Bionuclear
Services, Reading, UK) for the detection of B cells. In addition,
a standard alkaline phosphatase anti-alkaline phosphatase (APAAP)
method was used with the mAb BU38 (The Binding Site Ltd.,
Birmingham, UK) for the demonstration of CD23.
Cell Surface Immunofluorescence of Tumor Cell Suspensions.
￿
For
the preparation ofviable cell suspensions, lumps oftumor weighing
-200 mg were cut into several small pieces with a scalpel, re-
suspended in RPMI 1640 tissue-culture medium (no serum) con-
taining 0.05% collagenase (No. C9891; Sigma Chemical Co.), and
agitated for 45 min at 37°C. The cell suspension was separated
away from the remaining undigested tissue and washed twice in
medium containing 10% FCS. Typically, at least 10-20 x 106
viable cells were recovered. These cells were labeled with mAbs
specific for cell surface antigens, followed by FITC-conjugated goat
anti-mouse IgG antibodiesas described (29). The stained cells were
analyzed on a FRCS 440 (Becton Dickinson & Co., Mountain View,
CA). The panel of mAbs used included 55 (CD10, CALLA), AC2
(CD39), RRA (CD54, ICAM-1), and TS2/9 (CD58, LFA3); these
mAbs were used in an earlier study to characterize the cell surface
phenotype of BL cells (29).
Southern Blot Analysis for Ig Gene Rearrangements.
￿
DNA was
prepared from snap-frozen biopsy material (30) and 10 hg DNA
was digested with Bg1II restriction enzyme (Bethesda Research
Laboratories, Gaithersburg, MD). The digested DNA was electro-
phoresed on a 0.8% agarose slab gel and transferred to Hi Bond
N* filters (Amersham Corp., Arlington Heights, IL) by capillary
blotting in 0.4 M NaOH. Filters were prehybridized at 65°C for
4 h in 2x SSPE (360 mM NaCI, 20 mM Na2HPO,, 2 mM
EDTA), 5% dextran sulphate, 1% SDS, 0.5% dried skim milk.
Random primed '2P-labeled Ck probe and 100 Ag/ml denatured
salmon sperm DNA were added and the hybridization was con-
tinued for 20 h. The Ck probe was a 0.75-kb HindIII/EcoRI in-
sert ofpRH10, a gift from TH. Rabbitts, MRC, Cambridge, UK.
Filters were washed in 2 x SSC (150 mM NaCl, 15 mM sodium
citrate) for 15 min at 20°C, for a further 20 min at 60°C in 1x
SSC, with 1% SDS, and briefly in 0,5x SSC with 1% SDS at
60°C. Hybridized probe was detected by autoradiography of the
filters for up to 10 d using Kodak X-Omat S film.
Immunofuorescencefor Human K and A Ig Light Chains on Frozen
Tissue Sections.
￿
Acetone-fixed cryostat sections of 5 um thickness
Epstein-Barr Virus-associated Lymphomas in the Human/SCID Mousewere rehydrated with PBS containing 20% normal goat serum
(PBS/NGS), and then incubated for 1 h at 37°C with a mixture
ofTRITC-conjugated goat antibodies to K Ig light chains and FITC-
conjugated goat antibodies to X Ig lightchains (Nordic Immuno-
logical Laboratories Ltd.), diluted 1:10 in PBS/NGS. After washing
the slides in PBS, they were mounted in DABCO-based anti-fading
mountant (31) and visualized by fluorescence microscopy.
Immunofluorescence for EBV Antigens on Frozen Tissue Sections.
The following mAbs were used for the detection ofvirally encoded
proteins: CS.1-4 (anti-LMP) (32), PE2 (anti-EBNA 2) (11), JF186
(anti-EBNA-LP) (33), BZ.1 (anti-BZLFl) (Young, L. S., R. Lau,
M. Rowe, et al., manuscript in preparation), and V3 (antiVCA)
(34). Methanol-fixed cryostat sections of 5 Am thickness were re-
hydrated with PBS containing 20% normal rabbit serum (PBS/
NRS) and incubated with specific mAbs for 2 h at 37°C. Bound
mAb was detected by incubation with FITC-conjugated goat
anti-mouse IgG (No. F0257; Sigma Chemical Co.) for 1.5 h at
37°C, followed by washing in PBS, and then for a further 1 h at
37°C with FITC-conjugated rabbit anti-goat IgG (No. F2016;
SigmaChemical Co.). The mAbs were diluted either 1:1(hybridoma
culture supernate) or 1:100 (ascitic fluids) in PBS/NRS, while the
FITC conjugates were diluted 1:50 in PBS/NRS containing 10%
EBVseronegative human serum. The slides were finally washed
in PBS, mounted in DABCO-based anti-fading mountant (31), and
visualized by fluorescence microscopy.
Western Blot Analysis for EBV Gene Expression.
￿
Frozen pieces
of tumor biopsies were prepared for Western blotting by first
homogenizing in ice-cold Ripa buffer (0.5% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS, 150 mM NaCl, 10 mM Tfis buffer pH
8.0) at 5% weight/volume, and then diluting with an equalvolume
of 2 x gel sample buffer (4% SDS, 10% S-mercaptoethanol, 0.02%
bromophenol blue dye, 0.1 M Tris buffer, pH 6.8). The samples
were then sonicated and boiled for 2 min and 40-Al aliquots were
loaded per trackfor electrophoresis. Control samples were prepared
from 106 washed cells from cultured cell lines by sonicating and
boiling in 20 P1 of 1x gel samplebuffer. SDS-PAGE on 7.5% acryl-
amide Laenunf gels, followed by blotting onto nitrocellulose filters,
probing with specific antibodies and detection with '21I-protein
A, was performed as described elsewhere (35). In addition to the
mAbs to EBV latent infection proteins described above, a poly-
specific human serum, PA from a chronic infectious mononucle-
osis patient was used to detect EBNA 2, EBNA 3a, EBNA 3b,
and EBNA 3c. Monospecific antibodies to EBNA 1 were affinity-
purified from pooled human sera by affinity chromatography on
a synthetic peptide, p107, which contains glycine/alanine repeat
sequences of EBNA'1 (36).
Immunofluorescence Testfor Anti-VCA Antibodies.
￿
Human IgG
antibodies to the EBVencoded viral capsid antigen complex (VCA)
were detected by a standard indirect immunofluorescence proce-
dure (37) using acetone-fixed smears of P3HR-1 (producer line)
and Raji cells (non producer line) as target antigens.
Results
In the main set of experiments, aliquots of 35-50 x 106
PBLs isolated from one ofeight EBVseropositivedonors were
injected intraperitoneally into SCID mice; some 17 animals
were reconstituted in this way. PBLs from all eight donors
gave rise to tumors; these arose in 14 (82%) ofthe mice within
a mean time of 83 ± 25 d (range 63-120 d). Multiple tumors
were often found, commonly presenting at the base of the
liver, in association with the gut, and in the thymus. Exten-
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sive necrosis of the liverand an enlarged spleen were observed
in all 14 tumor-bearing mice, as well as in one animal which
became sick at 5 wk with no obvious tumors. The remaining
two animals, together with three mice injected with PBLs
from an EBVseronegative donor, remainedhealthy after19-23
wk and showed no evidence of tumors at autopsy.
In a parallel set of experiments, LCLs first generated in
vitro, either by spontaneous transformation ofcultured PBLs
from seropositive donors or by experimental infection ofPBLs
from seronegative donors with EBV, were tested for their
ability to grow in SCID mice. All of these LCLs, with the
exception of the long-established X50-7 line, were from early-
passage cultures. Many of the LCLengrafted animals devel-
oped tumors (see later for details) and these were character-
ized along with the PBLderived tumors.
Histopathology of Tumors.
￿
Sections stained with hema-
toxylin-eosin revealed that PBLderived tumors in SCID mice
possessed identical morphology to tumors arising in SCID
mice injected with EBVtransformed cells from established
LCLs (Fig. 1, a and b). The neoplasms were composed of
a polymorphic mixture of lymphoplasmacytoid, lymphocytic,
immunoblastic, and plasmacytic cells. These appearances are
typical of polymorphic lymphoplasmacytoid non-Hodgkins
lymphoma (Kiel classification) . The morphology was iden-
tical for all tumors studied and is consistent with the histo-
logical description of EBV+ large cell lymphomas arising in
immunosuppressed patients (8, 9, 11, 12, 18).
Immunohistochemistry ofTurnom
￿
In the PBLderived tumors,
there were scant, scattered T cells of human origin which
stained with the mAbs UCHL1 (Fig. 1 c) and MT1 (data
not shown); these T cells were absent from the LCIrderived
tumors (Fig. 1 d). All specimens, whether of PBL or LCL
origin, labeled strongly with the pan-B mAbs L26 (Fig. 1,
e andf) and MB2 (data not shown), and with the anti-CD23
mAb BU38 (Fig. 1, g and h).
CellSurface Phenotype ofDispersed Tumor Cells.
￿
Viable cell
suspensions from collagenase-dispersed tumors were analyzed
for cell surface phenotype by indirect immunofluorescence
staining with mAbs. The four mAbs used were selected from
a panel previously used to discriminate between the pheno-
type of BL cells and LCL cells (15), and Fig. 2 shows FACS
profiles obtained with these mAbs. The tumor cells from hu-
PBLSCID mice were CD10- , but positive for the CD39 ac-
tivation antigen and the CD54 (ICAM-1) and CD58 (LFA3)
adhesion molecules (Fig. 2 A). In comparison with cells taken
from a culture of a spontaneous LCL from the same donor,
the fluorescence intensity of staining for CD39, CD54, and
CD58 was noticeably lower on the tumor cells from hu-PBL
SCID mice. However, a similar reduction of fluorescence in-
tensity was often observed in tumors derived from LCLs in-
jected into SCID mice. Thus, Fig. 2 B shows that PBILderived
tumors and LCLderived tumors display a similar cell surface
phenotype, and that this phenotype is distinct from that of
BL cells which are strongly CD10+ and essentially negative
for CD39, CD54, and CD58.
Clonality of the Tumors.
￿
Cryostat sections of 13 tumors
from PBLreconstituted SCID mice were stained for KIg light
chains using rhodamine-conjugatedpolyclonal antibodies andfor X light chains using FITC-conjugated polyclonal anti-
bodies. Five of the tumors appeared to be monoclonal by this
type of analysis, as illustrated by the tumor 2 derived from
donor PLo (Fig . 3 A), while three of the tumors were clearly
either polyclonal or oligoclonal, as illustrated by'the tumor
derived from donor Mike (Fig. 3 B) . Five other tumors stained
predominantly for one light chain . Analysis ofDNA rear-
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Figure 1 . Histopathological and im-
munophenotypic characterization of for-
malin-fixed paraffin-embedded sections
from tumors arising in a hu-PBLSCID
mouse (a, c, e, g) and in a hu-LCLSCID
mouse (b,d,f, h), respectively . Sectionswere
stained with hematoxylin/eosin (a, b) or
were immunostained with a panT cell mAb,
UCHLI (c, d), with a pan-B cell mAb, L26
(e,f), or with an anti-CD23 mAb, BU38
(g, h) .
rangements in the Ig gene locus, which is a more definitive
marker for B lymphoid clonality (38), confirmed that some
tumors were indeed monoclonal. Thus, Fig. 3B shows results
obtained with three independent tumors (all of which were
monoclonal by immunophenotyping) taken from one mouse
15 wk after engraftment with 35 x 106 PBLs from donor
PLo. In this eacample, theDNA was digested with Bg1II and
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hybridized with a Ck probe. DNA prepared from Hela cells
was used as a control unrearranged DNA sample, while spleen
cells from the hu-PBIrSCID mouse were largely composed
ofmurine cells and therefore DNA prepared from this tissue
did not hybridize with the probe. The pattern of hybridiza-
tion of the probewith DNA from the threePLo hu-PBI~SCID
tumors indicated that each tumor contained a single predom-
inant clone of B cells, and that individual tumors from the
same animal could be clonally distinct. A cell line (PLo Tumor
3c) that was established in culture from the PLo tumor 3
showed the same pattern of Ig gene rearrangement as the
original biopsy. The results obtained with the MRe tumor
(Fig. 3 B) were consistent with this tumor being polyclonal
or oligoclonal.
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log fluorescence intensity -->
Figure 2.
￿
FRCS profiles ofcollagenase-dispersed viable cells from SCID-hu tumors, stained for CD10 (CALLA), CD39, CD54 (ICAM-1), and CD58
(LFA-3). Fluorescence intensity is expressed on an arbitrary logarithmic scale. (A) SCID mouse tumor cells derived from PBLs ofdonor HGa, compared
with collagenase-treated cells of a cultured LCL established in vitro by spontaneous outgrowth PBLs of the same donor. (B) Cells from the Akata-BL
line, which has retained a BL biopsy-like phenotype, compared with SCID mouse tumors derived either from PBLs of donor ADa or from an in
vitro transformed LCL.
EBV LatentGene Expression in PBIrderiuedSCID Tumors.
￿
In
the first instance, EBV latent gene expression was investigated
by Western blot analysis of tumors usinga polyspecific human
serum, PB, with reactivityagainst several of the EBNAs. Fig.
4 A shows representative results ofsuch an analysis obtained
with two independent tumors derived from PBLs from donor
ADa; a spontaneous LCL, established from PBLs of the same
donor in vitro, was included for comparison. The PB serum
detected EBNA 2 and EBNA 3a,b,c proteins in both PBL
derived tumors, and the size of these proteins corresponded
exactly to those expressed in the ADa-spLCL, thus confirming
that these tumors carried the expected ADa EBV isolate. Note
that two reference LCLs included in the same immunoblot
carry different EBV isolates and express characteristicallyFigure 3 .
￿
(A) Immunophenotyping ofSCID mouse tumors derived from PBLs ofdonors PLo andMRe. Cryostat sections were analyzed by dichro-
matic fluorescence using polyclonal antibodies to Ig K (TRITC conjugate) and Ig X (FITC conjugate) . The two tumors correspond to PLo Tumor
2 and the MRe Tumor in the Southern blot illustrated in Figure B . (B) Southern blot of BgIII-digestedDNA, probed with aCK probe, demonstrating
Ig gene rearrangements in PBLderived hu-SCID tumors. The molecular size markers (kbp) are indicated to the right of the blot . DNA from the
Hela cell line, which served as a germline Ig gene control, was compared with DNA prepared from : the spleen (which lacked tumor cells) and three
independent tumors from one mouse inoculated with PBLs from donor PLo, and one tumor arising in a second mouse inoculated with PBLs from
donor MRe . In addition, an early-passage cultured line established in vitro from the PLo- tumor 3 was analyzed (PLo tumor 3c) .
different sized EBNA proteins, while the EBNA 2 and
EBNA 3a,b,c proteins were not detected in the EBV+ cell
line Akata-BL, reflecting its BL origin.
Expression of the other EBV latent proteins in PBLderived
tumors was examined further using monospecific or mono-
clonal reagents since these avoid the problems of interpreta-
tion such as are illustrated in Fig . 4 A in the 25-60-kD re-
gion of the blot where PB serum may be detecting either
EBNA-LP of the latent cycle, or the EA(D) complex of the
lytic cycle, or degradation products ofEBNAs 2 and 3 . Thus,
Fig. 4 B shows a similar blot probed with affinity-purified
human antibodies to EBNA 1, and demonstrates that the
same 2 representative ADa PBIrtumors expressed EBNA 1,
as did the referenceLCL andBL cell lines . Other blots probed
withmAbs to EBNA2 (data not shown), to EBNALP (Fig.
4 C), and to IMP (Fig. 4 D) demonstrated the presence of
these three latent viral proteins in the PBL tumors and in
the LCL lines, but not in the Akata-BL line. Note that the
JF186 anti-EBNA-LP mAb (Fig . 4 C) detects a ladder of
different sized proteins that is characteristic for a given line
but which may differ even between lines carrying the same
EBV isolate; this reflects the variable multiplicity of repeat
exons in differentEBNALP mRNAs (33, 39) . In addition,
the JF186 mAb is known to react only with the EBNALP
encoded by a minority of EBV isolates (e.g., the AMEBV
isolate, but not the isolate carried by the reference LCL 1
in Fig . 4 C) : of the eight donors used as a source ofPBLs
for theseSCID mouse studies, three donors carriedEBV iso-
lates encoding an EBNALP that was recognized by JF186,
and thehu-PBLSCID tumors derived from these donors were
thus shown to express EBNALP The expression ofEBNALP
in PBILderived tumors from the other donors was verified
using affinity-purified human antibodies (15) .
The expression ofEBV latent viral proteins in the majority
of cells in all SCID-hu tumors tested was readily confirmed
by immunofluorescence staining of cryostat tissue sections
with mAbs to IMP, EBNA 2, and EBNALP (Fig. 5) . PBL
derived tumors from each of the eight EBVseropositive donors
studied were shown, by one or both ofthe above techniques,
to express the latent viral proteins that are constitutively ex-
pressed in LCLs but not in BL cells.
EBV Lytic Cycle Gene Expression in PBLderived SCID
Tumors . Western blots of PBILderived tumors were probed
with a human serum, EE, which has high titer antibodies
to the immediate-early antigen BZLF1, and to the early an-
tigen complex EA(D) . As illustrated by the blot in Fig. 6,
all of the tumors were found to express lytic cycle antigens
to a greater or lesser extent . These data were confirmed by
immunfluorescence staining with mAbs to the BZLF1 pro-
tein and to the viral capsid antigen VCA, which revealed a
distinct subpopulation of antigen-positive cells distributed
unevenly throughout the tumors (Fig. 7) . Staining of cell
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showed that up to 5% of the cells within a tumor may be
in the virus-productive cycle (data not shown) . No background
reactivity was observed with these mAbs in normal tissues
lacking tumor cells .
Humoral Response to Late Viral Antigens in hu-PBLSCID
Mice.
￿
The virus-producer status of the PBL tumors in hu-
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Figure 4 .
￿
EBV latent proteins de-
tected in PBIrderived SCID mouse
tumors by Western blotting . Two in-
dependent tumors (tumor 1 and
tumor 2) and an in vitro-established
spontaneous LCL (spLCL) were all
derived from PBLs of donor ADa .
Other reference protein samples were
prepared from : an EBV- line (BL40),
two LCLs transformed with different
isolates of EBV (LCIA and LCIA),
and the Akata-BL line. The blots were
probed with: (A) serum PB, a poly-
specific human serum for the detec-
tion ofEBNA 2, EBNA 3a, EBNA
3b, and EBNA 3c; (B) monospecific
anti-p107 human antibodies to EBNA
1, isolatedby affinity chromatography
using a synthetic peptide correspond-
ing to an EBNA 1 repeated a .a . se-
quence; (C) JF186, a mAb reactive
with EBNA-LP; and (D) CS .1-4, a
pool ofmAbs reactive withLMP The
positions of molecular weight marker
proteins (sizes given in kilodaltons)
are indicated . Note that A shows a
deliberate over-exposure of the blot
in order to illustrate clearly the pres-
ence and size oftheEBNA 3 proteins
in the hu-SCID tumors from donor
ADa ; a shorter exposure also demon-
strated that the EBNA 2 protein in
the SCID tumors was the same size
as the EBNA 2 in the ADa sponta-
neous LCL .
PBIrSCID mice contrasts with the situation in man where
large celllymphomas arising in immunosuppressed patients
are apparently negative for productive cycle antigens (11, 12) .
Because these patients retain serum antibody responses to late
viral antigens, we tested the hu-PBIrSCID mice for similar
responses . HumanIgG antiVCA antibodies were monitored
in two mice, each injected with 40 x 10 6 PBLs from donorMRe (Table 1) . Low titers of antiVCA antibodies were de-
tected in both animals during the first 6 wk, but no anti-
bodies were detected when tumors were identified at 10-11
wk . In total, the sera from nine animals injected withPBLs
from five donors were tested at the time when killed, (range
10-23 wk), and antiVCA antibodies were invariably unde-
tectable .
Growth Properties o,fCultured LCLs in SCID Mice.
￿
Taken
together, the aforementioned data indicate that the tumors
Figure 6 .
￿
Western blot demonstratingthe expressionofEBV productive-
cycleproteins in PBI~derived tumors from SCID mice . The blot was probed
with the human serum EE, which has high titer antibodies to the BZLF1
immediate-early antigen and to components of the EA(D) early antigen
complex . In this blot, five independent tumors derived from PBLs of four
different donors (ADa, HGa, CMc, and MRe) are compared with extracts
from spleen and kidney tissue that did not show any evidence of tumors .
The B95.8 virus-producer cell line, which contains ti5% VCA+ cells, was
run on the same gel for reference.
154
Figure 5 . EBV latent proteins de-
tected in cryostat sections of a PBD
derived SCID mouse tumor (the same
as the PLo tumor 2, shown in Fig . 3)
by immunofluorescence staining with
specific mAbs .LMP was detected with
CS.1-4,EBNA 2 withPE2, andEBNA
LP with JF186.
arising in SCID mice reconstituted with PBLs actually
resemble in vitro-transformed LCL cells with respect to cel-
lular phenotype and viral gene expression . This was in one
sense surprising since it is well known that in vitro-trans-
formedLCL cells do notgrowwhen injected subcutaneously
or intraperitoneally into nude mice (40) . For this reason the
present experiments were extended to test whether LCLs,
like the PBIsderived tumors, were capable of growth inSCID
mice. In an initial set ofexperiments tumors regularly devel-
oped in SCID mice injected intraperitoneally with 5x 106
cells from each of three different LCLs. Two of these LCLs
were established spontaneously in vitro from thePBLs of the
EBVseropositive donors, MRe and HGa, and were used in
early passage (before passage 10), while the third LCL was
a long-established line, X50-7, obtained by deliberate infec-
tion of cord blood cells in vitro with EBV. Each of the spon-
taneous LCLs was injected into a set of three SCID mice,
while the X50-7 line was injected into two mice: all eight
mice produced multiple solid tumors within 27 d which were
histologically and phenotypically indistinguishable from PBI'
derived tumors (see Figs . 1 and 2) .
It is now clear that EBV isolates fall into two types (1 and
2), basedon polymorphism of their EBNA2 andEBNA 3a,
b, c genes (35, 41, 42); these viruses have slightly different
biological properties in vitro such that type 1 EBVtransformed
LCLs grow more quickly and to a higher saturation cell den-
Table 1 .
￿
Anti-VCA Antibodies in SCID Mice Injected with
PBLs from Donor MRe
Epstein-Ban Virus-associated Lymphomas in the Human/SCID Mouse
Serum sample
Donor human serum, day 0
Reciprocal anti-VCA titer
960
SCID-hu mouse-1 3 wk 40
6 wk 40
10 wk Negative
SCID-hu mouse-2 3 wk 20
6 wk 30
11 wk Negativesity than do type-2 transformants (28) . Because all of the
donors used as a source ofPBLs for the main set of experi-
ments were carrying the more common type 1 isolates of
EBV, and because the three LCLs tested initially for growth
in SCID mice were also type 1 transformants, we were in-
terested to investigate the capacity of type 2 transformants
to grow in this same environment . Therefore, eight different
LCLs, all established at the same time fromPBLs of a single
EBVseronegative donor by infection in vitro with different
type 1 and type 2 isolates of EBV (28), were compared for
their ability to induce tumors in SCID mice . The panel of
LCLs consisted of four lines infected with different type 1
EBV isolates and four lines infected with different type 2 EBV
isolates, all tested in early in vitro passage . Each LCL was
injected into a set of three mice and of the animals injected
with type 1 LCLs, 11 of 12 produced solid tumors within
a mean time of 30.2 ± 7.1 d (range 20-43 d) . In contrast,
only 2 of 12 animals injected with type 2 LCLs developed
tumors (at 38 and 52 d) ; the remaining 10 animals were healthy
at the time when killed (109 d) and lacked any evidence of
tumors at autopsy .
Discussion
The present analysis of human B cell lymphomas arising
in SCID mice engrafted with PBLs from healthy EBV
seropositive individuals shows that these tumors closely
resemble in vitro-transformed LCL cells and are distinct from
BL cells by histological appearance (Fig. 1), cell surface pheno-
type (Fig. 2), andEBV gene-expression (Figs . 4 and 5) . Fur-
thermore, conventional karyotyping of metaphase spreads from
three independent PBLderived monoclonal tumors revealed
normal diploidy and the absence of any chromosome trans-
locations characteristic ofBL (Stacey,M ., andM. Rowe, un-
published observations) . These results are in contrast to the
suggestion made in a recent report (25), based on one PBL
donor, that the tumors arising in SCID mice have some char-
acteristics ofBL : this particular donor may be an interesting
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Figure 7 .
￿
EBV productive cycle an-
tigens detected by immunofluorescence
staining ofcryostat sections ofthesame
PBLderived tumor as in Fig. 5 . The
BZLF1 protein was detected with the
mAb B2.1, andVCA was detectedwith
the mAb V3 .
exception to the general rule. In our cell surface phenotype
analysis, some PBIrderived tumors did show slightly reduced
expression of LCIrassociated markers such as CD39 and the
adhesion molecules (Fig . 2 A), but a similar reduction was
also observed in tumors generated in SCID mice after inocu-
lation with in vitro transformed LCLs (Fig. 2 B) . This minor
shift in cell surface phenotype appears to be a consequence
of the in vivo environment since lines established in culture
from the tumors reverted to their usual high levels of antigen
expression within a few in vitro passages (data not shown) .
By the above criteria of histological appearance, cell sur-
face phenotype, and EBV latent gene expression, the PBL
derived tumors in hu-PBLSCID mice are similar to EBV+
large cell lymphomas that arise in immunosuppressed indi-
viduals . The one interesting difference between these two
tumors is the unexpected finding that thelymphomas arising
in the hu-PBLSCID model contained a proportion of cells
expressingEBV antigens of the virus-productive cycle (Figs .
6 and 7) . Although Katz et al . (43) reported the presence
of linear (i.e., replicating) EBV DNA in -40% of EBV
associated lymphomas in immunosuppressed patients, early
and late viral proteins themselves have not been detected in
such biopsies to date (11, 12) . Similarly, EBV+ tumors in-
duced in cotton-top tamarins by experimental infection with
the virus in vivo do not express lytic cycle antigens, although
cell lines derived from the tamarin tumors do become virus-
productive in vitro (44) . The PBLderived tumors in SCID-
hu mice therefore provide the first documented evidence of
EBV productive cycle antigens being expressed in B cells in
vivo . Note that in this animal model there are no detectable
antibody responses to late viral antigens at the time of tumor
development (Table 1) . This distinguishes thehu-PBLSCID
model from both immunosuppressed humans and experimen-
tally infected tamarins, and raises the possibility that antibody-
mediated mechanismsmay normally repress or eliminate cells
entering the EBV productive cycle in vivo.
An important feature of the PBLderived SCID tumors is
their presentation as discrete foci at multiple anatomical sites,each focus often being composed of a single unique B cell
clone (Fig. 3); this feature is also shared by the large cell lym-
phomas in immunosuppressed patients (9, 17, 18). It has been
argued that the monoclonality of many of the EBV+ lym-
phomas in immunosuppressed patients reflects the occurrence
of a second genetic event, in addition to the essential EBV
driven proliferation, which results in clonal selection of the
malignant cells. However, the rapidity with which EBV+
monoclonal tumors lacking chromosomal abnormalities can
arise in the SCID mouse model, from an estimated input
of -25-50 EBVinfected B cells in 50 x 106 PBLs (27, 45),
seems to us to argue against a specific second malignant event
in the lymphomagenesis. It is well known that even during
EBVinduced B cell growth transformation in vitro, where
there is no obvious selection except on the basis of growth
rate, the original polyclonal LCL can soon become dominated
by one or a few clones with serial passage in culture (46) .
A similar selection on the basis of differential growth rates
could well operate in vivo, both in human-SCID chimeric
mice and in immunosuppressed patients. This is entirely in
line with our observation that LCLs generated in vitro by
infection with type-2 EBV isolates, and showing poorer in
vitro growth than corresponding type 1 transformants (28),
are much less efficient at forming tumors in SCID mice than
are type 1 transformants. This may have important implica-
tions sincetype 2 isolates are now known to be present within
Western communities, albeit at a much lowerincidence than
type 1 isolates (47). The inference is that immunosuppressed
patients with type 2, rather than a type 1, EBV infection
will be less susceptible to lymphoproliferative disease.
In many respects, EBVassociated lymphomagenesis in the
hu-PBIrSCID model reflects the situation in vitro when lym-
phocytes from healthy EBV carriers give rise to LCLs by spon-
taneous outgrowth. This leads to some interesting predic-
tions since it is known that such spontaneous outgrowth in
vitro occurs by a two-step mechanism; EBVinfected B cells
in the circulating pool enter the productive cycle on being
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